Treatments Using Venlafaxine
This; invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual, syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a: mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: in which A is a moiety of the formula where the dotted line represents optional unsaturation; R 1 is hydrogen or alkyl; R 2 is alkyl; R 4 is hydrogen, alkyl, formyl, or alkanol; R 5 and R 6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R 7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof:
1 . A method of treating bulimia nervosa in a mammal, comprising administering to the mammal an effective amount of a compound of the formula:
in which A is a moiety of the formula
wherein
the dotted line represents optional unsaturation;
R 1 is hydrogen or alkyl of 1 to 6 carbon atoms;
R 2 is alkyl of 1 to 6 carbon atoms;
R 4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl,, or alkanol of 2 to 7 carbon atoms;
R 5 and R 6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or taken together, methylene dioxy;
R 7 is hydrogen or alkyl of 1 to 6 carbon atoms; and
n is 0, 1, 2, 3, or 4;
or a pharmaceutical acceptable salt thereof.
2 . The method of claim 1 wherein the mammal is a human.
3 . The method of claim 1 wherein the composition is administered orally.
4 . A method of treating bulimia nervosa in a mammal, comprising administering to the mammal a pharmaceutical composition comprising an effective amount of a compound of the formula:
in which A is a moiety of the formula
wherein
the dotted line represents optional unsaturation, and
R 1 is hydrogen or alkyl of 1 to 6 carbon atoms;
R 2 is alkyl of 1 to 6 carbon atoms;
R 4 is hydrogen, alkyl oft to 6 carbon atoms, formyl, or alkanol of 2 to 7 carbon atoms;
R 5 and R 6 are, independently, hydrogen, hydroxy), alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms; dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or taken together, methylene dioxy;
R 7 is hydrogen or alkyl of 1 to 6 carbon atoms; and
n is 0, 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
5 . The method of claim 4 wherein the compound is:
in which A is a moiety of the formula
wherein
the dotted line represents optional unsaturation and
R 1 is hydrogen or alkyl of 1 to 3 carbon atoms;
R 2 is alkyl of 1 to 3 carbon atoms;
R 5 is hydrogen, hydroxyl, alkoxy of 1 to 3 carbon atoms, chloro, bromo, trifluoromethyl or alkyl of 1 to 3 carbonatoms;
R 6 is alkyl of 1 to 3 carbon atoms; alkoxy of 1 to 3 carbon atoms, chloro, bromo, trifluoromethyl or alkanoyloxy of 2 to 3 carbon atoms;
R 7 is hydrogen or alkyl of 1 to 3 carbon atoms;
or a pharmaceutically acceptable salt thereof.
6 . The method of claim 1 wherein R 5 and R 6 are both in the meta positions or one of R 5 or R 6 is in the para position and n is 2.
7 . The method of claim 1 wherein the compound is 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.
8 . The method of claim 1 wherein the compound is 1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.
9 . The method of claim 1 wherein the effective amount comprises a daily dose of between about 50 mg/day and about 375 mg/day.
10 . The method of claim 1 wherein the effective amount comprises a daily dose of between about 75 mg/day and about 200 mg/day.
11 . The method of claim 1 wherein the mammal is a human.
12 . The method of claim 1 wherein the pharmaceutical composition is administered orally.
13 . The method of claim 1 wherein the pharmaceutical composition is in a unit dosage form which is a tablet.
14 . The method of claim 1 wherein the pharmaceutical composition is in a unit dosage form which is a capsule.